Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Claim review
AOD-9604 fat-loss claims — claim review
AOD-9604 is the modified C-terminal fragment of HGH originally developed by Metabolic Pharmaceuticals for obesity. It failed Phase 3 trials but persists as a popular cosmetic-clinic and online-supplement weight-loss product. This page covers what the evidence actually shows.
What people claim
- “Targeted fat loss without growth hormone side effects”
- “FDA GRAS-approved fat loss” (misrepresents the GRAS food-ingredient status)
- “Stack with semaglutide for accelerated fat loss”
Evidence honestly
Phase 3 obesity development of AOD-9604 did not produce a licensed product. Meaningful body-composition benefit was not demonstrated at trial scale. Off-label cosmetic-clinic use has no published RCT to support the marketed effects.
Safer alternatives
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS or registered private prescriber.
- NHS Tier 2 / 3 weight-management programmes.
- Structured diet, resistance training, and cardio — the evidence-based body-recomposition stack.
Frequently asked questions
- Did AOD-9604 ever become a licensed weight-loss drug?
- No. AOD-9604 failed Phase 3 obesity trials and did not progress to a licensed obesity product anywhere in the world.
- Is AOD-9604 'safe' because it has GRAS status?
- AOD-9604 has US FDA GRAS (Generally Recognised As Safe) status as a food ingredient — that is not the same as a medicine licence. GRAS status does not authorise injectable medical use or weight-loss claims.
- Does it produce meaningful fat loss in cosmetic clinics?
- Clinic-marketing claims outrun the trial evidence. Failed Phase 3 obesity development is the most relevant signal — meaningful clinical fat-loss benefit was not demonstrated at scale.
- Is it WADA-prohibited?
- AOD-9604 is treated as a growth-hormone-fragment compound; WADA position is class-prohibited. Athlete strict liability applies.
- Why is it still marketed?
- GRAS status and 'lipolytic HGH fragment' positioning create a memorable story for clinic and online marketing. The underlying efficacy evidence does not support weight-loss claims.